Home › Myelodysplastic Syndromes
Myelodysplastic Syndromes clinical trials recruiting in the U.S.
157 studies for Myelodysplastic Syndromes are recruiting participants at sites across the United States.
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
Cities with the most studies
- Houston, TX43 studies
- Baldwin Park, CA26 studies
- Seattle, WA21 studies
- New York City, NY21 studies
- Washington, DC20 studies
- Boston, MA19 studies
- Tampa, FL19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- Durham, NC14 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
- St. Louis, MO13 studies
- Cleveland, OH11 studies
- Nashville, TN11 studies
- Philadelphia, PA10 studies
- Birmingham, AL10 studies
- Los Angeles, CA10 studies
- Mountain View, CA9 studies
- Baltimore, MD9 studies
- Pittsburgh, PA9 studies
- Winston-Salem, NC9 studies
- Jacksonville, FL9 studies
- The Bronx, NY9 studies
- Portland, OR8 studies
- Buffalo, NY8 studies
- New Haven, CT8 studies
- Milwaukee, WI8 studies
- Minneapolis, MN8 studies
- Salt Lake City, UT8 studies
- Memphis, TN7 studies
- Clifton, NJ7 studies
- Cedar Rapids, IA7 studies
- Edison, NJ7 studies
- Orange, CA7 studies
- Kansas City, MO7 studies
- San Francisco, CA6 studies
- Aurora, CO6 studies
- Rochester, NY6 studies
- Queens, NY6 studies
By state
- Alabama10 studies
- Arizona9 studies
- Arkansas4 studies
- California41 studies
- Colorado8 studies
- Connecticut10 studies
- District of Columbia4 studies
- Florida31 studies
- Georgia15 studies
- Hawaii3 studies
- Idaho4 studies
- Illinois16 studies
- Indiana4 studies
- Iowa7 studies
- Kansas5 studies
- Kentucky5 studies
- Louisiana5 studies
- Maine4 studies
- Maryland23 studies
- Massachusetts21 studies
- Michigan8 studies
- Minnesota13 studies
- Mississippi3 studies
- Missouri15 studies
- Montana3 studies
- Nebraska4 studies
- Nevada3 studies
- New Hampshire5 studies
- New Jersey13 studies
- New Mexico4 studies
- New York38 studies
- North Carolina19 studies
- North Dakota4 studies
- Ohio22 studies
- Oklahoma4 studies
- Oregon10 studies
- Pennsylvania17 studies
- Rhode Island4 studies
- South Carolina7 studies
- Tennessee15 studies
- Texas44 studies
- Utah8 studies
- Vermont3 studies
- Virginia8 studies
- Washington21 studies
- West Virginia4 studies
- Wisconsin11 studies
Recently updated studies
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
RecruitingPhase 1/2
Ages 12 to 120 · All sexes · Updated Oct 2, 2026 · NCT06303193Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06577441Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06904066Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
RecruitingObservational study
1 Day – 99 Years · All sexes · Updated Oct 2, 2026 · NCT07683104Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06484062Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RecruitingPhase 1/2
Ages 4 to 75 · All sexes · Updated Oct 1, 2026 · NCT03173937The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695CHIP/CCUS Natural History Protocol
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT04102423MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06548230Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03661307Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RecruitingPhase 2
Ages 4 to 80 · All sexes · Updated Sep 22, 2026 · NCT01174108Natural History Study of GATA2 Deficiency and Related Disorders
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 22, 2026 · NCT01905826A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07422480Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 18, 2026 · NCT03630991CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04375631Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187Collection of Tissue Samples for Cancer Research
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04771130From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.